NCT02211872已完成1 期
An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 63
- 主要终点
- Maximum tolerated dose (MTD) for a single dose of BI 2536 BS
研究概览
简要总结
The primary objective of this study was to determine the maximum tolerated dose (MTD) of BI 2536 BS in patients with advanced solid tumours. Secondary objectives were the evaluation of safety, efficacy, and pharmacokinetics of BI 2536 BS
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with confirmed diagnosis of advanced, non resectable and / or metastatic solid tumours, who had failed conventional treatment, or for whom no therapy of proven efficacy exists, or who were not amenable to established forms of treatment
- •Evaluable tumour deposits
- •Age of 18 years or older
- •Life expectancy of at least 6 months
- •Written informed consent consistent with international conference of harmonization (ICH) - good clinical practice (GCP) and local legislation
- •Eastern Cooperative Oncology Group (ECOG, R01-0787) performance score ≤ 2
- •And full recovery from all therapy-related toxicities from previous chemo-, hormone-, immuno-, or radiotherapies
排除标准
- •Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial protocol
- •Pregnancy or breastfeeding
- •Active infectious disease
- •Known brain metastases
- •Second malignancy requiring therapy
- •Absolute neutrophil count less than 1500/mm3
- •Platelet count less than 100 000/mm3
- •Bilirubin greater than 1.5 mg/dL (> 26 μmol/L, international system of units (SI) equivalent)
- •Aspartate amino transferase (AST) and / or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases greater than five times the upper limit of normal)
- •Serum creatinine greater than 1.5 mg/dL (> 132 μmol/L, SI unit equivalent)
- •Sexually active women and men who are unwilling to use a medically acceptable method of contraception
- •Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
- •Chemo-, radio or immunotherapy within the past four weeks before start of therapy or concomitantly with this trial
- •Patients unable to comply with the trial protocol
- •Or active alcohol or drug abuse
研究组 & 干预措施
Treatment B
Experimental
BI 2536 BS multiple rising doses on three consecutive days (d1-3 schedule)
干预措施: BI 2536 BS, intravenous (Drug)
Treatment A
Experimental
BI 2536 BS single rising dose
干预措施: BI 2536 BS, intravenous (Drug)
结局指标
主要结局
Maximum tolerated dose (MTD) for a single dose of BI 2536 BS
时间窗: Up to 16 weeks
MTD for single doses of BI 2536 BS on 3 consecutive days
时间窗: Up to 16 weeks
次要结局
- Time from dosing to maximum concentration of BI 2536 BS in plasma (tmax)(Pre-dose, up to 216 hours after drug administration)
- Apparent volume of distribution during the terminal phase λz following an intravascular dose (Vz)(Pre-dose, up to 216 hours after drug administration)
- Amount of BI 2536 BS that is eliminated in urine from the time point 0 to time point 24/48 (Ae0-24/48)(Pre-dose, up to 48 hours after drug administration)
- Terminal rate constant in plasma (λz)(Pre-dose, up to 216 hours after drug administration)
- Total clearance of BI 2536 BS in the plasma after intravascular administration (CL)(Pre-dose, up to 216 hours after drug administration)
- Maximum concentration of BI 2536 BS analyte in plasma (Cmax)(Pre-dose, up to 216 hours after drug administration)
- Area under the concentration-time curve of BI 2536 BS in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)(Pre-dose, up to 216 hours after drug administration)
- Number of patients with adverse events(Up to 1 year)
- Mean residence time of BI 2536 BS in the body after intravenous administration (MRT)(Pre-dose, up to 216 hours after drug administration)
- Fraction of analyte eliminated in urine from time point 0 to time point 24/48 (fe0-24/48)(Pre-dose, up to 48 hours after drug administration)
- Assessment of objective treatment response by tumour measurements(Up to 1 year)
- Percentage of the AUC0-∞ that is obtained by extrapolation (%AUC0-tz)(Pre-dose, up to 216 hours after drug administration)
- Terminal half-life of BI 2536 BS in plasma (t1/2)(Pre-dose, up to 216 hours after drug administration)
- Apparent volume of distribution at steady state following intravascular administration (Vss)(Pre-dose, up to 216 hours after drug administration)
- Renal clearance of BI 2536 BS from the time point 0 to time point 24/48 (CLR,0-24/48)(Pre-dose, up to 48 hours afterdrug administration)
研究者
相似试验
已完成
1 期
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid TumoursNeoplasmsNCT02273388Boehringer Ingelheim65
已完成
1 期
Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid TumorsTumorsNCT00298675Sanofi59
已完成
1 期
Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma PatientsMultiple MyelomaNCT02514239Boehringer Ingelheim43
终止
1 期
Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic CancerPancreatic NeoplasmsNCT02215044Boehringer Ingelheim12
已完成
1 期
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid CancersNeoplasmsNCT00969553Boehringer Ingelheim59